Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Nyxoah ( (NYXH) ).
On September 18, 2025, Nyxoah SA announced the entry into an underwriting agreement for a public offering of ordinary shares, with Morgan Stanley, Stifel, and Cantor Fitzgerald as underwriters. The offering, expected to close around September 23, 2025, aims to raise funds for the commercialization of the Genio system in the U.S. and other markets, support clinical research, and finance R&D activities. This strategic move is expected to bolster Nyxoah’s market positioning and operational capabilities, potentially impacting stakeholders positively by extending the company’s cash runway into late 2026 or 2027.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR14.50 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for treating Obstructive Sleep Apnea (OSA). Their primary product, the Genio system, offers a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA, a common sleep disorder associated with increased mortality risk and cardiovascular comorbidities.
Average Trading Volume: 68,921
Current Market Cap: €160.6M
Find detailed analytics on NYXH stock on TipRanks’ Stock Analysis page.